Affiliation:
1. Jiading District Central Hospital Affiliated Shanghai University of Medicine and Health Sciences, Shanghai, China
2. Nanjing Medical University, Nanjing, China
Abstract
Introduction
This study aimed to evaluate the prognosis of patients with COVID-19 and hypertension who were treated with angiotensin-converting enzyme inhibitor (ACEI)/angiotensin receptor B (ARB) drugs and to identify key features affecting patient prognosis using an unsupervised learning method.
Methods
A large-scale clinical dataset, including patient information, medical history, and laboratory test results, was collected. Two hundred patients with COVID-19 and hypertension were included. After cluster analysis, patients were divided into good and poor prognosis groups. The unsupervised learning method was used to evaluate clinical characteristics and prognosis, and patients were divided into different prognosis groups. The improved wild dog optimization algorithm (IDOA) was used for feature selection and cluster analysis, followed by the IDOA-k-means algorithm. The impact of ACEI/ARB drugs on patient prognosis and key characteristics affecting patient prognosis were also analysed.
Results
Key features related to prognosis included baseline information and laboratory test results, while clinical symptoms and imaging results had low predictive power. The top six important features were age, hypertension grade, MuLBSTA, ACEI/ARB, NT-proBNP, and high-sensitivity troponin I. These features were consistent with the results of the unsupervised prediction model. A visualization system was developed based on these key features.
Conclusion
Using unsupervised learning and the improved k-means algorithm, this study accurately analysed the prognosis of patients with COVID-19 and hypertension. The use of ACEI/ARB drugs was found to be a protective factor for poor clinical prognosis. Unsupervised learning methods can be used to differentiate patient populations and assess treatment effects. This study identified important features affecting patient prognosis and developed a visualization system with clinical significance for prognosis assessment and treatment decision-making.
Funder
Shanghai Key Specialty Project of Clinical Pharmacy
Nature Science Foundation of Jiading District, Shanghai
Shanghai University of Medicine and Health Sciences Clinical Research Centre for Metabolic Vascular Diseases Project
Reference41 articles.
1. COVID-19, vaccines and deficiency of ACE2 and other angiotensinases. Closing the loop on the Spike effect;Angeli;European Journal of Internal Medicine,2022
2. Chi-square test under indeterminacy: an application using pulse count data;Aslam;BMC Medical Research Methodology,2021
3. COVID-19: discovery, diagnostics and drug development;Asselah;Journal of Hepatology,2021
4. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial;Bauer;The Lancet Respiratory Medicine,2021
5. Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial;Bhandari;Nephrology, Dialysis, Transplantation,2016
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献